Skip to main content
. Author manuscript; available in PMC: 2020 Jan 9.
Published in final edited form as: J Am Chem Soc. 2018 Dec 17;141(1):251–261. doi: 10.1021/jacs.8b09198

Figure 6. Xenograft Tumor Distribution of Avidity-Modulated CSANs.

Figure 6.

(A) EpCAMHigh MCF-7 and EpCAMLow MDA-MB-231 xenograft tumors were resected, weighed, and counted for activity 18 h after IV infusion of avidity modulated CSANs. Activity values were time-corrected to 18 h to account for continued decay during the weighing/counting process. Data is presented as the mean ± standard deviation of the mice (n = 3) in each treatment group. Unless specified otherwise, statistical relevance marks comparison of the indicated sample to the 0:8 T:NT sample for that tumor, as determined by a two-tailed Student’s t-test. For clarity, intertumoral comparisons that failed to reach statistical significance are not marked. (B) The ratio of CSAN uptake in the MCF-7 tumors to MDA-MB-231 tumors is plotted on the primary y-axis (bar graph, linear scale). The corresponding MCF-7:MDA-MB-231 ratio of median fluorescence intensity values obtained in the in vitro studies (Fig. 5) are plotted along the secondary y-axis (line graph, log scale). Data is presented as the mean ratio ± standard deviation for three mice (in vivo) or independent trials (in vitro).